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Abstract
Background: A homeostatic relationship with the intestinal microflora is increasingly appreciated as essential for human
health and wellbeing. Mutations in the leucine-rich repeat (LRR) domain of Nod2, a bacterial recognition protein, are
associated with development of the inflammatory bowel disorder, Crohn’s disease. We investigated the molecular
mechanisms underlying disruption of intestinal symbiosis in patients carrying Nod2 mutations.
Methodology/Principal Findings: In this study, using purified recombinant LRR domains, we demonstrate that Nod2 is a
direct antimicrobial agent and this activity is generally deficient in proteins carrying Crohn’s-associated mutations. Wild-
type, but not Crohn’s-associated, Nod2 LRR domains directly interacted with bacteria in vitro, altered their metabolism and
disrupted the integrity of the plasma membrane. Antibiotic activity was also expressed by the LRR domains of Nod1 and
other pattern recognition receptors suggesting that the LRR domain is a conserved anti-microbial motif supporting innate
cellular immunity.
Conclusions/Significance: The lack of anti-bacterial activity demonstrated with Crohn’s-associated Nod2 mutations in vitro,
supports the hypothesis that a deficiency in direct bacterial killing contributes to the association of Nod2 polymorphisms
with the disease.
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Introduction
Crohn’s disease is a chronic relapsing inflammatory bowel
disorder characterised by transmural and discontinuous lesions of
the intestinal tract [1],[2]. It is generally accepted that the
characteristic gut inflammation of Crohn’s (as well as ulcerative
colitis) is the result of a robust immune response against
commensal bacteria in the gastrointestinal tract. Currently, it is
not clear what underlies this loss of tolerance, however patients
demonstrate increased levels of attaching/effacing and intracellu-
lar bacteria consistent with an initiating role for bacteria in the
pathogenesis of the disease [3]. Environmental factors (such as
smoking) as well as genetic factors also play a role in disease
pathogenesis [4]. Genome-wide linkage studies of Crohn’s disease
families initially identified a susceptibility locus on chromosome 16
[5]. This linkage was subsequently confirmed as being a result of
mutations in the intracellular pattern recognition receptor (PRR)
Nod2 [6]. Three distinct Nod2 single nucleotide polymorphisms
(SNPs) have been associated with increased risk of developing
Crohn’s disease. All three are coding mutations contained within
(G908R, 3020insC), or adjacent to (R702W), the LRR domain at
the C-terminus of the protein. LRR domains are common to
many PRRs and are believed to confer sensitivity to pathogen-
associated molecular patterns (PAMPs).
Results
Unlike H. pylori’s part in the pathogenesis of stomach ulcers, a
single pathogen associated with development of Crohn’s disease
has not been demonstrated although several have been proposed
[7]. Due to their constant exposure to the microbiota of the
gastrointestinal tract, epithelial cells are the primary point of
contact with the commensal flora. In order to investigate the
mechanism by which Nod2 protects the gastrointestinal tract,
polyclonal antibodies were raised against recombinant human
Nod2 LRR domains and used to examine the localisation of
endogenous Nod2 in an intestinal epithelial cell line incubated
with a non-pathogenic Escherichia coli strain (Figure 1a). In the
absence of bacteria, Nod2 was expressed at low levels and
distributed throughout the cytosol (Figure S1). Following incuba-
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10915Figure 1. Nod2, but not the Crohn’s-associated 3020insC mutation, directly associates with bacteria. A, SW480 intestinal epithelial cells
were used to investigate the distribution of endogenous Nod2 protein following inoculation of the cells with E.coli (ATCC 25922) at an MOI of 1000:1.
Cells were processed for immunofluorescence using a polyclonal antibody raised against the LRR domain of Nod2, immunopurified on the antigen
and further processed on an E.coli lysate column to remove contaminating anti-bacterial antibodies. Controls are shown in Figure S1 demonstrating
specificity of the Nod2 antibody. Bar=15 mm. B, E.coli expressing GFP were generated by transformation of ATCC 25922 with a cDNA encoding GFP
in pUC19. SW480 cells were treated as described in Figure 1a. An antibody against GFP was used to enhance the GFP signal although the fluorescent
protein was generally visible (centre top panel). Isotype antibody control for GFP (chicken IgY) and rabbit IgG processed on an E.coli lysate column
were used as controls (centre panels). Bar=30 mm. C, Association of His-tagged recombinant protein derived from cDNAs encoding Nod2 LRR, Nod2
3020insC LRR and Nod1 LRR domains with E.coli. 10 ng of each protein was added to approximately 10
6 bacteria in 100 ml of LB media, incubated for
30 minutes at room temperature, and the samples centrifuged at low speed to collect the bacteria and associated proteins. The bacterial pellet and
supernatants were reconstituted in equal volumes and loaded on an SDS-PAGE gel. Following transfer to nitrocellulose, the samples were analysed
by Western blot using an anti-His antibody (Sigma). D, Direct binding of Nod2, but not Nod2 3020insC, to E.coli in vitro. Recombinant Nod2, Nod2
3020insC or Nod1 LRR domains (35 mg/ml) were added to E.coli at 37uC overnight. Bacteria were collected by centrifugation, washed and the
association of LRR domains determined by immunofluorescent labelling of the bacteria with anti-Nod2 antibody (described in Figure 1a) and goat
anti-rabbit 2u antibody. A sample of the labelled bacteria were placed on a sealed coverslip and analysed by fluorescent microscopy. Insets
demonstrate the presence of comparable numbers of bacteria in each of the images as demonstrated by DAPI staining. Bar=10 mm.
doi:10.1371/journal.pone.0010915.g001
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of the cells (Figure 1a, Figure S1). The observed Nod2-positive
structures were consistent with the size and characteristic shape of
E.coli and were co-stained with DAPI. The presence of these
bacteria inside the exposed cells was surprising considering the
strain used (FDA strain Seattle 1946 [DSM 1103, NCIB 12210,
ATCC25922]) is a biosafety level 1 bacterium that, to our
knowledge, has not demonstrated any previous evidence of
pathogenic potential. We next generated GFP-expressing E.coli
and repeated the experiment to confirm that Nod2 was recruited
to bacteria-containing structures within the cell (Figure 1b). Nod2
is generally believed to be a sensor of muramyl dipeptide (MDP), a
component of the bacterial proteoglycan coat. Until now, a direct
interaction between Nod2 and bacteria has not been demonstrat-
ed. We tested this possibility in vitro and confirmed that
recombinant Nod2 LRR domains associated directly with E.coli
using two different assays for direct bacterial binding. Recombi-
nant Nod2, Nod2 3020insC and Nod1 LRR domains were
incubated with E.coli, collected by centrifugation, and the
distribution of the Nod2 and Nod1-derived proteins in the
bacterial pellet and/or supernatant determined by Western blot
(Figure 1c). This assay demonstrated a significant accumulation of
Nod2 LRR domains with the bacterial pellet. This association was
not observed using the 3020insC LRR domain. Nod1 LRR also
distributed with the bacterial pellet demonstrating that it too can
directly recognise bacteria. In addition, purified LRR domains of
Nod2 were associated with E. coli as demonstrated by staining of
the bacteria with an antibody raised against the LRR domain of
Nod2 (Figure 1d). Incubation of bacteria with Nod1 LRR domains
did not give significant staining above background (Control)
despite Nod1 LRR domain association with E.coli (Figure 1c)
demonstrating the specificity of the antibody for Nod2. The LRR
domains containing the 3020insC polymorphism could not be
detected on the bacteria above background levels suggesting this
Crohn’s-associated polymorphism confers an inherent defect in
bacterial recognition. Direct interaction of the Nod2 LRR domain
with the gram-positive bacteria E. faecalis was also demonstrated
(Figure S2).
We next investigated the consequences of the observed LRR
interaction with bacteria. Following overnight treatment of various
bacterial strains with Nod2 LRR domains, a pellet could be
observed in the bottom of the treated, but not control tubes (not
shown). Examination of the pellet by microscopy revealed
aggregation of LRR-treated bacteria suggesting Nod2 LRR
domains were directly influencing the phenotype of a broad range
of bacteria (Figure S3). Therefore, we sought to identify and
quantitate the impact of the Nod2 LRR domains on exposed
bacteria. E.coli was cultured in LB media in the presence of the
Nod2 LRR domains for 6 hours and the metabolic profile of the
bacteria assessed. Metabolomic analysis revealed that Nod2 LRR
domains induced significant and specific perturbations to cellular
metabolism (Figure 2,Table S1). Theseincluded a 3-foldincrease in
c-aminobutyrate, a 40–50% decrease in glutamate, aspartate and
glutathione and a 2-fold increase in trimethylamine oxide (TMAO).
The loss of glutathione would be expected to be detrimental to cell
survival as glutathione is central to the regulation of intracellular K
+
and detoxification of methylglyoxal in E.coli [8]. The loss of cellular
glutamate and aspartate coupled with an increase in c-aminobu-
tyrate suggests the induction of amino acid decarboxylases
consistentwithcytoplasmicacidification [9].LRRdomainscarrying
the 3020insC did not induce similar perturbations to the cellular
metabolite profile suggesting proteins with Crohn’s-associated
mutations cannot target bacterial metabolism due to their lack of
direct binding to the bacteria (Figure 1).
Previous reports have shown that Nod2 can protect cultured
cells from bacterial infection and this activity is deficient in cells
expressing the 3020insC polymorphism [10]. In addition, mice
deficient in Nod2 (as well as mice carrying the equivalent mutation
to the human 3020insC polymorphism) are more susceptible to
infection by various bacteria [11]–[13]. Based on these reports and
our own observations, we hypothesized that Nod2, directly binds
to bacteria and kills them via the LRR domain. E.coli were
incubated with increasing doses of the recombinant LRR domains
of either Nod2 or Nod2 3020insC and the integrity of the bacterial
membrane evaluated using a flow cytometric assay previously used
to study the activity of anti-bacterial defensins [14]. Incubation
with wild-type Nod2 LRR domain resulted in membrane
depolarisation indicative of anti-bacterial activity (Figure 3a). This
activity could not be observed with the Nod2 3020insC LRR
domains. While E.coli were only partially susceptible to Nod2-
induced membrane depolarisation, gram positive B. subtilis were
completely depolarised by less than 10 mg/ml Nod2 (Figure 3b).
Again, this activity was deficient when the 3020insC LRR domain
was used. Since LRR domains of Nod1 could also directly bind to
bacteria (Figure 1c), we hypothesised that the observed anti-
bacterial activity for Nod2 might be a common property of LRR
domains derived from pattern-recognition receptors. LRR do-
mains from Nod1, Naip, Nalp3, CIITA and TLR2 were generated
and their activity against B.subtilis assessed in the membrane
depolarisation assay (Figure 3c). Nod1 demonstrated comparable
efficacy against the bacteria as Nod2. Naip, Nalp3 and TLR2
LRR domains all demonstrated significant activity in this assay –
although this was not as robust as with Nod2 and Nod1 against
B.subtilis.
We further extended our analysis of Nod2 anti-bacterial activity
using a variety of established anti-bacterial assays to confirm our
initial observations. In an agar-diffusion assay anti-bacterial
activity of Nod2 could be observed with a clear zone of growth
exclusion of B.subtilis and S. aureus surrounding a well containing
purified LRR domains (Figure 3c). We did not observe any
evidence of anti-bacterial activity using LRR proteins carrying the
3020insC mutation while Nod1 LRR domains also demonstrated
a clear efficacy in this assay. Anti-bacterial activity was also tested
using an in vitro assay based on the correlation of ATP levels with
bacterial number (Table S2). Comparing Nod2 and Nod1 anti-
bacterial activity in this assay demonstrated clear differences in
bacterial specificity. For example, Nod2 effectively targeted E.
faecalis while Nod1 was selective over Nod2 for K. pneumoniae. Not
all bacteria were insensitive to the 3020insC LRR domain. Indeed,
the activity of Nod2 and Nod2 3020insC was comparable against
L. monocytogenes. This assay was also used to investigate the anti-
bacterial activity of the Crohn’s-associated G908R Nod2 poly-
morphism. L. monocytogenes continued to proliferate in the presence
of the G908R LRR domain but was sensitive to the 3020insC
domains. However, the anti-bacterial activity was not completely
deficient in the G908R protein since it targeted B. subtilis with
comparable efficacy to the 3020insC LRR (although this activity
was deficient compared to the wild-type LRR domains).
The most pronounced observation was the clear sensitivity of
the aerobic gram-positive bacteria tested in this assay to the Nod2
LRR domain. This was not observed when anaerobic bacteria
were tested for LRR sensitivity in a standard minimal inhibitory
concentration (MIC) assay. This assay assesses the potency of
antibiotics by determining the minimal concentration at which no
visible bacterial growth can be observed. The sensitivity of 9
anaerobic bacterial strains to Nod2 and Nod1 LRR domains using
this assessment are presented in Table 1. All bacteria were
insensitive to the presence of LRR domains containing the
Antimicrobial Activity of Nod2
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was comparable with a standard broad-range antibiotic (Cipro-
floxacin). On a molar basis, Nod1 and Nod2 were potent against
the majority of anaerobic bacteria tested with Nod2 LRR MICs
ranging from approximately 30 nM (P. anaerobius)t o4mM( B.
thetaiotamicron). This establishes the Nod proteins as among the
most potent endogenous anti-microbial peptides yet identified
[15].
Discussion
These results have major implications for the pathogenesis of
Crohn’s disease. The compromised anti-bacterial activity demon-
strated by the Crohn’s-associated LRR domains should be
considered alongside the signalling properties of the protein in
any model of the molecular mechanisms associated with Nod2’s
role in Crohn’s disease. Normal physiological events such as stress
are associated with the onset of relapse in IBD patients and have
been demonstrated to increase epithelial barrier permeability
resulting in elevated levels of intracellular bacteria in normal
animals [16],[17]. Breech of the epithelial barrier by bacteria
would necessitate a response by the host to the invading microbe
and Nod2 has a recognised role in coordinating innate immune
responses to intracellular bacteria. In the context of Nod2 SNPs,
the data presented would support the hypothesis that initial
recognition and potential lysis of the intracellular bacteria by
Nod2 is deficient in genetically defined patient populations. It is
conceivable that this could lead to persistent infection of the host
by the bacteria. A robust immune response would then be initiated
by redundant bacterial-sensing pathways in the host to contain
and deal with the infection. This could account for the relapsing,
remitting and focal character of the inflammation observed in
Crohn’s disease patients. Inflammatory responses are essential to
maintaining a barrier between the host and its environment. The
direct recognition of bacteria by Nod2 likely triggers a cellular
inflammatory response to breech of host defences by potential
pathogens. While polymorphisms in the Nod2 LRR domains
confer sensitivity to developing Crohn’s disease, mutations in the
Nod2 NACHT domain are associated with other inflammatory
disorders, such as Early-Onset Sarcoidosis and Blau syndromes
[18],[19]. This leads us to speculate that the Nod2 Nacht domain
mutations may mimic in part an association of the protein with
bacteria resulting in an elevated basal cellular anti-bacterial
signaling response (in the absence of a bacterial infection). The
Nod2 Nacht domain mutations are associated with eye, joint and
skin, but not intestinal inflammation whereas the Crohn’s-
associated LRR domain polymorphisms are generally associated
with intestinal, but not with extraintestinal, manifestations. Our
Figure 2. Nod2 LRR domains impact bacterial metabolism. A, Expansion of
1H-NMR spectrum (d
1H 3.1 to 2.0 ppm) of cell extracts from
Control (BSA treated), Nod2 LRR and Nod2 3020insC LRR domains as indicated. B, Metabolic perturbation induced by Nod2 LRR and Nod2 3020incC
LRR treatment in E. Coli. GABA; c-aminobutyrate, Glu; glutamate, Asp; aspartate, GSH; glutathione, Tyr; tyrosine, Pyr; pyruvate, TMAO; trimethylamine
oxide. All metabolite changes indicated with Nod2 LRR were statistically significant versus control E.coli (p,0.05, Student’s T-test). The data are
summarised in Table S1. C, Principle component analysis (PCA) score plot of E.coli metabolism treated as indicated with LRR domains from Nod2,
Nod2 3020insC or BSA. PCA of the NMR data was performed using SIMCA-P v.10 (Umetrics AB, Umea ˚, Sweden). This data reduction method allows the
visualization of the effect of treatment on the cellular metabolism, the clustering of groups of data is based solely on the similarity of the input
spectral data. Each symbol represents the
1H-NMR spectrum of an individual cell extract. The axis, principal component 1 (t[1]) and 2 (t[2]), represent
the top two most abundant correlated variation within the data set. The separation of the WT LRR from the Control and 3020incC LRR cells is due to
specific perturbations in cellular metabolism.
doi:10.1371/journal.pone.0010915.g002
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LRR domain in the Nacht domain mutants suppressing any
initiating bacterial infection in the gut that might lead to a
Crohn’s-like phenotype.
The discovery of a direct anti-microbial activity for Nod2 and
Nod1 offers an explanation for the protection against bacterial
infection conferred by expression of these proteins in cell lines and
is consistent with the increased sensitivity of Nod2 knockout mice
to Mycobacteria, Listeria and Salmonella infection [10]–[13], [20].
These data also have implications for infectious diseases associated
with other LRR domain-containing proteins. Using B. subtilis as a
model organism, we observed anti-bacterial activity using LRR
domains derived from Nalp3, NAIP and TLR2 indicating that the
LRR domain is a common anti-bacterial motif. Significant effects
Figure 3. Bacterial killing by purified Nod2 LRR domains is deficient in the Crohn’s-associated Nod2 3020insC mutant. Results shown
are all representative of several experiments. A,B, Nod2 LRR domains influence the membrane polarity of E.coli and B.subtilis. Proteins were added at
the concentration indicated to 5610
5 bacteria in 100 mL growth medium and incubated for 2 hours at 37uC. 15 minutes prior to the end of the time
course, 50 mlo f1 0mg/ml DiBAC4 solution was added to each well. Plates were washed twice with 750 ml ice cold PBS/well. The percentage of
depolarised bacteria taking up the dye was determined by flow cytometry. C, Anti-bacterial activity of Nod1 and Nod2 but not Nod2 3020insC LRR
domains demonstrated by agar diffusion assay. Agar plates were inoculated with a lawn of the indicated bacteria. Approximately 0.5 cm diameter
holes were punched into the agar with a sterile glass pipette and the indicated protein (BSA protein control or indicated LRR domain) or antibiotic
(ampicillin or kanamycin) added to each well at a concentration of 0.5 mg/ml in sterile PBS. D, B. subtilis membrane polarity is influenced by the LRR
domains from a range of pattern-recognition receptors. Bacteria were treated with the indicated LRR domains as described for Figure 3a and their
effect on the membrane polarity of the bacteria evaluated.
doi:10.1371/journal.pone.0010915.g003
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LRR domains using an ATP-based assay supporting this
conclusion (Figure S4). Distinct categories of bacteria demonstrat-
ed sensitivity to different LRR domains suggesting that the LRR
domains of individual PRRs have evolved to provide resistance to
potential infection by specific pathogens. While many bacteria
may be targeted directly by the LRR domains of the proteins that
were tested, obvious candidates for future investigation are
Mycobacteria for Nod2, Legionella pneumophila for NAIP and
Mycobacterium leprae for TLR2 due to the evidence associating
these proteins with susceptibility to infection in cells, animal
models and their genetic links with patient populations [13],[21]–
[26]. Nod2 deficiency in mice is associated with susceptibility to
Mycobacterial infection [13]; a genus we did not consider in our
study but one that has been debated as a candidate pathogen for
Crohn’s disease [27]–[29]. Nod2 SNPs associated with Mycobac-
terial infections are in general distinct from those observed in
Crohn’s disease or the Crohn’s disease SNPs confer protection
against Mycobacterial-dependent diseases [23],[24]. In addition, the
Nod2-activating muramyl dipeptide motif in the bacterial
proteoglycan coat is absent in Mycobacteria, although this does
not preclude interaction of Nod2 with other PAMPs present on
Mycobacteria [25]. Other SNPs identified in the leprosy, tuberculosis
and Crohn’s-susceptibility studies have identified common genes
including IRGM, LRRK2 and TNFSF15 suggesting that a theme
of host microbial defence underlies the pathogenesis of these
diseases [23],[24],[30],[31].
Leucine-rich repeats are a conserved domain used in PRRs in
most organisms and direct anti-bacterial activity may also play a
significant role in innate defence against pathogens in plants via
the R proteins [32]. Furthermore, agnathan fish possess an
adaptive immune system based entirely on clonal rearrangement
of LRRs rather than immunoglobulins and the resulting LRR
domains demonstrate specificity for individual strains of bacteria
[33]–[36]. Our data would predict that at least some of these LRR
domains confer resistance to bacterial (and other microorganisms)
infection by direct interaction and termination of the pathogen.
This potential may underlie the conserved evolutionary develop-
ment of the LRR domain as a PRR-associated motif.
In conclusion, our study has revealed a previously unappreci-
ated anti-microbial activity for the LRR domains in a range of
PRRs. Indeed, the clear association of Nod2 polymorphisms with
defective bacterial killing suggests this function could significantly
underlie the contribution of commensal flora to the pathogenesis
of Crohn’s disease. In addition, the direct anti-microbial effects
demonstrated with other LRR domains suggest that direct
recognition and termination of pathogens underlies the association
of PRRs with susceptibility to infectious diseases and offers a
rationale for PRR links with the development of autoimmune
diseases. Efforts are now required to understand the role of Nod2
anti-microbial activity in vivo and reconcile this with known
inflammatory signalling pathways.
Materials and Methods
DNA cloning
The LRR domains of Nod1, Nod2 and Nod2 3020insC, Nalp3,
NAIP, CIITA and TLR2 were generated by PCR using primers
flanking the LRR domain. The PCR fragments encompassed
nucleotides 2275 to 3124 of Nod2 (NM_022162), nt2165 to
nt3286 of Nod1 (NM_006092), nt2856 to nt3857 of Nalp3
(NM_004895), nt3692 to nt4930 of NAIP (NM_004536), nt2204
to nt3526 of CIITA (NM_000246) and nt58 to nt1983 of TLR2
(NM_003264). The integrity of all inserted fragments were
confirmed by DNA sequencing.
Protein purification
The LRR domains of Nod1, Nod2 and Nod2 3020insC, Nalp3,
NAIP, CIITA and TLR2 were cloned in pDEST17 (Invitrogen)
expressed in Escherichia coli Rossetta (DE3) cells (Novagen) and
purified from inclusion bodies. The bacteria pellet were solubilized
using Guanidine-HCl 6M and affinity purified by chromatography
on a Ni–NTA column. Protein refolding was performed by a fast
10 fold dilution in PBS. A final purification step was performed
using a HiLoad 16/60 Superdex 200 size-exclusion column.
Purified proteins were visualized by Coomassie blue staining. The
LRR domains were generally unstable, aggregated and demon-
strated significant degradation upon storage. Nevertheless, com-
parable antibacterial activity was consistently demonstrated with
over 20 individual protein preps.
Antibodies
Anti-Nod2 rabbit antisera recognising recombinant human
LRR domains purified from bacteria were generated by Euro-
gentec. Antibodies recognising the antigen were purified from the
serum using a Nod2 LRR domain protein column and passed
through a bacterial affinity column (Pierce) to remove contami-
nating anti-bacterial antibodies.
Table 1. LRR domain anti-bacterial activity against anaerobes.
Nod1 LRR Nod2 LRR 3020insC LRR Ciprofloxacin
B.fragilis 16-32 (4) 4-32 (5) .128 (3) 8 (2)
B.thetaiotamicron 64-128 (3) 32-128 (4) .128 (3) 64 (1)
F.nucleatum 16-64 (2) 8-.128 (3) .128 (2) 2 (1)
P.intermedia 8 (1) 4-8 (2) .128 (1) 1 (1)
E.lentum 16 (1) 8-16 (2) .128 (1) 2 (1)
C.perfringens 16-32 (3) 4-32 (4) .128 (3) 2 (2)
C.difficile* 16-32 (3) 4-32 (5) 128-.128 (3) 8 (3)
P.anaerobius 2 (1) 1-2 (2) .128 (1) 1 (1)
P.acnes 8 (1) 4-8 (2) .128 (1) 1 (1)
Minimal Inhibitory Concentrations mg/ml [lowest – highest (n)],
*data is composite of testing against three different strains.
doi:10.1371/journal.pone.0010915.t001
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Bacterial viability was evaluated by standard MIC assay
protocol in accordance with NCCLS standards [37]. The
BacTiter-Glo microbial assay (Promega) was performed following
the manufacturers instruction. Bacterial membrane depolarisation
was assessed using a variation of the procedure previously
described by Nuding and colleagues [14]. Agar diffusion assay
was performed by placing purified protein in a well constructed in
an agar plate containing an inoculated lawn of bacteria.
High-resolution 1H-NMR
Cells were extracted with methanol/chloroform/water (1:1:0.9)
as previously described [38]. High-resolution
1H-NMR spectra
were acquired using standard pulse sequences at 30061 K using a
Bruker-600 Avance spectrometer (
1H frequency of 600.26 MHz).
1H-NMR spectra were acquired with 256 FIDs, 65,536 complex
data points, a spectral width of 7.2 kHz, and a relaxation delay of
1 s. Metabolite assignments were made on the basis of previous
reported data and in certain cases confirmed by spiking [39].
Supporting Information
Figure S1 Nod2 localisation of endogenous protein in SW480
intestinal epithelial cells in response to bacteria. SW480 cells were
inoculated with E.coli (ATCC 25922) at an MOI of 1000:1 as
indicated and incubated for 2 hours. Cells were examined by
immunofluorescence with aNod2 polyclonal antibody (generated
and affinity purified as described in Figure 1) or rabbit IgG
(processed over E.coli affinity column to remove E.coli interacting
antibodies), FITC-conjugated phalloidin to detect actin and
stained with DAPI to detect DNA (nucleii and bacterial DNA).
Nod2 is distributed at low levels throughout the cytoplasm of
unstimulated cells and colocalizes with intracellular bacteria
following incubation with E.coli.
Found at: doi:10.1371/journal.pone.0010915.s001 (0.20 MB
PDF)
Figure S2 Immunofluorescent detection of recombinant Nod2
LRR domains with E.faecalis. Bacteria were incubated with either
BSA (left panel) or Nod2 LRR domains (35 mg/ml; centre and
right panels). Bacteria were processed and analysed using either
anti-Nod2 antibody (left and centre panels) or without primary
antibody (right panel) as controls. Insets demonstrate the presence
of bacteria following staining with fluorescent membrane dye in
each of the images. Bar=50 mm.
Found at: doi:10.1371/journal.pone.0010915.s002 (0.31 MB
PDF)
Figure S3 Bacterial aggregation following incubation with
recombinant Nod2 LRR domains. Bacteria were incubated
overnight with 1 mg/ml (a,c,e) or 20 mg/ml (g) of BSA or equal
concentrations of purified Nod2 LRR domains (b,d,f,h). a–f,
Treated bacteria were incubated with membrane dye to help
visualisation. Each sample was mixed by vortexing, a sample
placed on a coverslip and observed by fluorescent microscopy. a,b,
Staphylococcus aureus, c,d, Streptococcus pneumoniae, e,f, Enterococcus
faecalis. g–h, E.coli were incubated as described above and
visualised by phase microscopy.
Found at: doi:10.1371/journal.pone.0010915.s003 (0.16 MB
PDF)
Figure S4 TLR2 and Nalp3 LRR domains inhibit L.monocyto-
genes viability as demonstrated by ATP-coupled luminescent assay.
L.monocytogenes (5X10
5 bacteria/100 ml) were incubated with
increasing concentrations of the indicated recombinant LRR
domains for 6 hours at 37uC and ATP levels assessed by
luminescent assay (BacTiter-glo: Promega). Values shown are
relative to controls incubated in the absence of LRR domains
(100%). Results are representative of two experiments for TLR2
and Nalp3. Recombinant LRR domains derived from CIITA and
NAIP showed no activity in a single assay up to 50 mg/ml.
Found at: doi:10.1371/journal.pone.0010915.s004 (0.05 MB
PDF)
Table S1 Metabolite levels in treated E. coli (mmol/mg dry wt).
Found at: doi:10.1371/journal.pone.0010915.s005 (0.03 MB
DOC)
Table S2 LRR anti-bacterial activity against aerobic bacteria.
Found at: doi:10.1371/journal.pone.0010915.s006 (0.04 MB
DOC)
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